# ARKANSAS REGISTER



# **Transmittal Sheet**

Use only for **FINAL** and **EMERGENCY RULES** 

Secretary of State

John Thurston

500 Woodlane, Suite 026 Little Rock, Arkansas 72201-1094 (501) 682-5070



www.sos.arkansas.gov

For Office Use Only:		
-	Code Number	
Name of Agency Arkansas Department	t of Health	
Department Pharmacy Services		
Contact Laura Shue	_ <sub>E-mail</sub> _Laura.Shue@arkansas.gov <sub>_I</sub>	Phone 501-661-2155
Statutory Authority for Promulgating Rul	es § 20-7-109 et seq.	
Rule Title: List of Controlled S	Substances	
Intended Effective Date		Date
Emergency (ACA 25-15-204)	Legal Notice Published	11/13/20
10 Days After Filing (ACA 25-15-204)	Final Date for Public Comment	12/15/20
Other	Reviewed by Legislative Council	3/23/21
(Must be more than 10 days after ning date.)	Adopted by State Agency	10/22/20
Electronic Copy of Rule e-mailed from: (Require	d under ACA 25-15-218)	
	nue@arkansas.gov	4/6/21
Contact Person	E-mail Address	Date
I Hereby Certi	on of Authorized official for That The Attached Rules Were Adopted kansas Administrative Act. (ACA 25-15-201 et Signature  Laura.Shue@arkansas.gov  E-mail Address  General Counsel  Title 4/6/21  Date	<del></del>

List Of Controlled Substances



For the State Of Arkansas Pursuant to the provisions of Arkansas Code Annotated § 5-64-201 and § 5-64-216 of the laws of the State of Arkansas, the Director of the Arkansas Department of Health or duly authorized agent, as specified by law, is giving public notice of the publication of the List of Controlled Substances for the State of Arkansas.

Due consideration has been given applicable federal regulations, current scientific knowledge regarding the listed substances, the evidence of actual or relative potential for abuse, the history and current patterns of abuse, the risk to the public health, and potential to produce psychic or psychological dependence liability.

Based on these considerations the attached listing of the Schedule of Controlled Substances and the corresponding drugs that are included in each schedule is hereby promulgated by the Director of the Arkansas Department of Health as the List of Controlled Substances for the State of Arkansas.

Each controlled substance or basic class thereof has been assigned an "Administration Controlled Substance Code Number" for purposes of identification. These numbers are for internal management and are used as a means to identify substances with complex and cumbersome chemical names.

Next to the code number is the date the substance was placed in schedule by the Director of the Arkansas Department of Health.

I, Shane David, Pharm.D., Section Chief of Pharmacy Services for the Arkansas Department of Health, do hereby certify that the documents attached hereto are true and correct copies of the current List of Controlled Substances adopted by the Arkansas State Board of Health in accordance with Arkansas state law.

Shane David, Pharm.D., Section Chief
Pharmacy Services Section

STATE OF ARKANSAS

COUNTY OF SALINE

I, Marci Middleton, do hereby certify that Shane David, Pharm.D., well known to me, appeared before me and signed the above referenced document.

Sworn and subscribed to before me this

Notary Public

My commission expires

MARCI MIDDLETON MY COMMISSION # 12403633 EXPIRES: April 25, 2025 Saline County

# ARKANSAS DEPARTMENT OF HEALTH

# LIST OF CONTROLLED SUBSTANCES

# SECTION I AUTHORITY

The following scheduling of these controlled substances has been hereby promulgated pursuant to Arkansas Stat. Ann. \$5-64-201\$ and \$5-64-216\$.

# SECTION II PURPOSE

Due consideration has been given applicable Federal regulations, current scientific knowledge regarding the listed substances, the evidence of actual or relative potential for abuse, the history and current patterns of abuse, the risk to the public health, and potential to produce psychic or psychological dependence liability.

# SECTION III GENERAL REQUIREMENTS

(Attached copy of the listing of scheduling of controlled substances)

#### SECTION IV REPEAL

All lists of schedules of controlled substances in conflict herewith are hereby repealed.

#### CERTIFICATION

This will certify the following list of scheduling of controlled substances was adopted by the Arkansas State Board of Health at a session of the Board held in Little Rock, Arkansas on the 22<sup>nd</sup> day of October, 2020, and after a Public Hearing on the 15<sup>th</sup> day of December, 2020, held in Little Rock, Arkansas, at the State Department of Health Building.

Osé R. Romero, M.D.,

Secretary of Health, Arkansas Department of Health

# ARTICLE II

# Schedule I

- (a) Schedule I shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. Each drug or substance has been assigned the DEA Controlled Substances Code Number set forth opposite it.
- (b) Opiates: (Narcotic Drugs) Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, salts is possible within the specific chemical designation (for purposes of 3-methylthiofentanyl only, the term isomer includes the optical and geometric isomers):

(1) Acetyl-alpha-methylfentanyl(N-[1-[1-methyl-2-	•
<pre>phenethyl)-4-piperidinyl]-N-phenylacetamide)</pre>	<b></b> 9815-(2-86)
(2) Acetylmethadol	
(3) Allylprodine	9602*
(4) Alphacetylmethadol (except Levo-alphacetylmet	hadol
(LAAM)	
(5) Alphameprodine	9604*
(6) Alphamethadol	9605*
(7) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta	-phenyl)
ethyl-4-piperidyl]propronanilide; 1-(1-methyl	
2-phenylethyl)-4(N-propanilido)piperidine)	9814-(6-82)
(8) Alpha-methylthiofentanyl(N-[1-methyl-2-(2thie	nyl)
ethyl-4-piperidinyl]-N-phenylpropanamide)	9832-(2-86)
(9) Benzethidine	9606*
(10) Betacetylmethadol	
(11) Beta-hydroxyfentanyl(N-[1-(2-hydroxy-2-phenet	hyl)
-4-piperidinyl[]-N-phenylpropanamide)	9830-(2-86)
(12) Beta-hydroxy-3-methylfentanyl	
[other name: N-[1-(2-hydroxy-2-phenethyl)-3-m	ethyl-
4-piperidinyl]-N-phenylpropamamide]	
(13) Betameprodine	
(14) Betamethadol	
(15) Betaprodine	
(16) Clonitazene	
(17) Dextromoramide	
(18) Diampromide	
(19) Diethylthiambutene	9616*
(20) Difenoxin	
(21) Dimenoxadol	
(22) Dimepheptanol	9618*
(23) Dimethylthiambutene	9619*
(24) Dioxaphetyl butyrate	9621*
(25) Dipipanone	
(26) Ethylmethylthiambutene	
(27) Etonitazene	
(28) Etoxeridine	
(29) Furethidine	
(30) Hydroxypethidine	
(31) Ketobemidone	
(32) Levomoramide	
(33) Levophenacylmorphan	
(34) 3-Methylfentanyl (N-[3-Methyl-1-(2-phenylethyl	
piperidyl]-N-Phenylpropanamide)	
(35) 3-methylthiofentanyl (N-[(3-methyl-1-(2-thieny	λŢ)

	ethyl-4-piperidinyl]-N-phenylpropanamide)	
(36)	Morpheridine	
(37)	MPPP (1-methyl-4-phenyl-4-propionoxypiperidine)	
(38)	Noracymethadol	
(39)	Norlevorphanol	9634*
(40)	Normethadone	
(41)	Norpipanone	9636*
(42)	Para-fluorofentanyl (N-[4-fluorophenyl)-N-[1-(2-	
	phenenthyl)-4-piperindinyl]propananmide	9812-(11-86)
(43)	PEPAP 1-(2-phenylethyl)-4-phenyl-4 acetyloxypiper-	
	idine	
(44)	Phenadoxone	
(45)	Phenampromide	
(46)	Phenomorphan	
(47)	Phenoperidine	9641*
(48)	Piritramide	
(49)	Proheptazine	9643*
(50)	Properidine	
(51)	Propiram	
(52)	Racemoramide	9645*
(53)	Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-	
	piperidinyl]-propanamide	9835-(2-86)
(54)	Tilidine	
(55)	Trimeperidine	9646*
(56)	Acetyl fentanyl N-(1-phenethylpiperidin-4-yl)	
	-N-phenylacetamide	-9821
(57)	Butyryl fentanyl N-(1-phenethylpiperidin-4-yl)	
	-N-phenylbutyramide	-9822
(58)	Beta-hydroxythiofentanyl N-{1-[2-hydroxy-2-	
	(thiophen-2-yl)ethyl]piperidin-4-yl}-N-	
	phenylpropionamide	-9836
(59)	Acetyl fentanyl 4-methylphenethyl analog N-	
	{1-[2-(4-methylphenyl)ethyl]-4-piperidinyl}-N-	
	phenyl-acetamide	
(60)	Valeryl fentanyl N-phenyl-N[1-(2-phenylethyl)	
	-4-piperidinyl]-pentanamide	
(61)	Furanyl fentanyl N-(1-(2-phenylethyl)-	
	4-piperidinyl) -N-phenylfuran-2-carboxamide	-9834
(62)	Isobutyryl fentanyl 2-methyl-N-phenyl-N-	
	[1-(2-phenylethyl)-4-piperidinyl]-propanamide	
(63)	Ocfentanil N-(2-fluorophenyl)-2-methoxy-N-[1-(2-	
	phenylethyl)piperidin-4-yl]acetamide	-9838
(64)	4-methoxy butyryl fentanyl N-(4-methoxyphenyl)-N	
	-(1-phenethylpiperidin-4-yl)butyramide	
(65)	Para-fluorobutyryl fentanyl N-(4-fluorophenyl)-N-	
	[1-(2-phenylethyl)-4-piperidinyl]-butanamide	9823
(66)	Acetyl norfentanyl N-phenyl-N-4-piperidinyl-acetami	
(67)	AH-7921 3,4-dichloro-N-[(1dimethylamino)cyclohexyl	
	methyl]benzamide	
(68)	W-18 1-(4-nitrophenylethyl)piperidylidene-2-(4-	
	chlorophenyl) sulfonamide	
(69)	W-15 1-phenylethylpiperidylidene-2-(4-chlorophenyl)	
•	sulfonamide	
(70)	MT-45 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine	
(71)	U-47700 trans-3,4-dichloro-N-(2-(dimethylamino)	
•	cyclohexyl)-N-methylbenzamide	
(72)	Acryl fentanyl N-(1-phenethylpiperidin-4-yl)-N-	
. ,	phenylacrylamide	9811
(73)		

- (74) Tetrahydrofuranyl fentanyl N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide----- 9843
  (75) Cyclopropyl fentanyl N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide ----- 9845
- (76) Methoxyacetyl fentanyl 2-methoxy-N-(1-
- phenethylpiperidin-4-yl)-N-phenylacetamide ----- 9825 (77) Ortho-fluorofentanyl N-(2-fluorophenyl)-N-(1phenethylpiperidin-4-yl)propionamide ----- 9816
- (78) Fentanyl-related substances, their isomers, esters, ethers, salts and salts of isomers, esters and ethers. Fentanyl-related substance means any substance not otherwise listed, and for which no exemption or approval is in effect under section 505 of the Federal Food, Drug, and Cosmetic Act[21 U.S.C. 355], that is structurally related to fentanyl by one or more of the following modifications:
  - (A) Replacement of the phenyl portion of the phenethyl group by any monocycle, whether or not further substituted in or on the monocycle;
  - (B) Substitution in or on the phenethyl group with alkyl, alkenyl, alkoxyl, hydroxyl, halo, haloalkyl, amino or nitro groups;
  - (C) Substitution in or on the piperidine ring with alkyl, alkenyl, alkoxyl, ester, ether, hydroxyl, halo, haloalkyl, amino or nitro groups;
  - (D) Replacement of the aniline ring with any aromatic monocycle whether or not further substituted in or on the aromatic monocycle; and/or
  - (E) Replacement of the N-propionyl group by another acyl group.
- (c) Opium derivatives: (Narcotic Drugs) Unless specifically excepted or unless listed in another schedule, any of the following opium derivatives, its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:
  - Acetorphine ----- 9319\* (1)(2) Acetyldihydrocodeine ----- 9051\* (3) Benzylmorphine ----- 9052\* (4) Codeine methylbromide ----- 9070\* (5) Codeine-N-Oxide ----- 9053\* (6) Cyprenorphine ----- 9054\* (7)Desomorphine ----- 9055\* Dihydromorphine ----- 9145\* (8) Drotebanol ----- 9335\* (9) (10)Etorphine (except hydrochloride salt) ----- 9056\* (11)Heroin ----- 9200\* Hydromorphinol ----- 9301\* (12)Methyldesorphine ----- 9302\* (13)(14)Methyldihydromorphine ----- 9304\* (15)Morphine methylbromide ----- 9305\* Morphine methylsulfonate ----- 9306\* (16)(17)Morphine-N-Oxide ----- 9307\* Myrophine ----- 9308\* (18)(19)Nicocodeine ----- 9309\* (20)Nicomorphine ----- 9312\* Normorphine ----- 9313\* (21)(22)Pholcodine ----- 9314\* (23)Thebacon ----- 9315\* (24)Mitragynine

# (25) 7-Hydroxymitragynine

(10)

(12)

(13)

(16)

(18)

DET.

MDEA.

(11)

(d) <u>Hallucinogenic substances</u> : Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation, which contains any quantity of the following hallucinogenic substance, or which contains any of its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation (for purposes of this paragraph only, the term "isomer"
includes the optical, position and geometric isomers):
(1) alpha-ethyltryptamine 7249-(12-93)
Some trade or other names: etryptamine; Monase; alpha-ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl)
indole; alpha-ET; and AET.
(2) 4-bromo-2,5-dimethoxy-amphetamine 7391*
Some trade or other names: 4-bromo-2,5-dimethoxy-
alpha-methylphenethylamine; 4-bromo-2,5-DMA.
(3) 4-bromo-2,5-dimethoxyphenethylamine 7392-(8-95)
Some trade or other names: 2-(4-bromo-2,5-dimethoxyphenyl)-1
aminoethane; alpha-desmethyl DOB; 2C-B, Nexus.
(4) 2,5-dimethoxyamphetamine 7396*
Some trade or other names: 2,5-dimethoxy-alpha-
methylphenethylamine; 2,5-DMA.
(5) 2,5-dimethoxy-4-ethylamphetamine 7399-(3-88)
Some trade or other names: DOET.
(6) $2,5$ -dimethoxy- $4$ -(n)-propylthiophenethylamine $7348$ -(1-05)
Some trade or other names: 2C-T-7.
(7) 4-methoxyamphetamine 7411*
Some trade or other names: 4-methoxy-alpha-
methylphenethylamine; paramethoxyamphetamine; PMA.

(8) 5-methoxy-3,4-methylenedioxy-amphetamine ----- 7401\*
 (9) 4-methyl-2,5-dimethoxyamphetamine ----- 7395\*
 Some trade and other names: 4-methyl-2,5-dimethoxy-

Some trade or other names: N- ethy-alpha-methyl-3,4 (methylenedioxy) phenethylamine, N-ethyl MDA; MDE;

Some trade or other names: N-hydroxy-alpha-methyl-3, 4(methylenedioxy) phenethylamine; N-hydroxy MDA
(14) 3,4,5-trimethoxy amphetamine ----- 7390\*

(17) Bufotenine ----- 7433\*

dimethylaminoethyl)-5-indolol; N,N-dimethylserotonin;

Some trade or other names: N, N-Diethyltryptamine;

(19) Dimethyltryptamine ----- 7435\*

Diethyltryptamine ----- 7434\*

(20) 5-methoxy-N, N-diisopropyltryptamine ----- 7439-(7-05)

3,4-methylenedioxy amphetamine ----- 7400\*

3,4-methylenedioxymethamphetamine ----- 7405-(10-85)

3,4-methylenedioxy-N-ethylamphetamine ------ 7404-(6-90)

N-hydroxy-3,4-methylenedioxyamphetamine ----- 7402-(6-90)

alpha-methyltryptamine ----- 7432-(7-05)

(15) 5-methoxy-n,n-dimethyltryptamine 5-MeO-DMT----- 7431\*(01-11)

alphamethylphenethylamine; "DOM"; and "STP".

Some trade or other names: MDMA)

Some trade or other names: AMT

Some trade or other names: DMT

Some trade and other names: 3-(beta-

Dimethylaminoethyl)-5-hydroxyindole; 3-(2-

5-hydroxy-N, N-dimethyltryptamine; mappine.

	Some trade or other names: 5-MeO-DIPT.	
(21)	Ibogaine	7260*
	Some trade and other names: 7-Ethyl-6,6 beta; 7,8,9,	
	10,12,13-octahydro-2-methoxy-6,9-methano-5H-pyrido	
	[1',2': 1,2] azepino [5,4-b] indole; Tabernanthe	
(22)	iboga. Lysergic acid diethylamide	7215+
(23)	Mescaline	7313^
	Parahexyl	
(24)	Some trade or other names: 3-Hexyl-1-hydroxy-	/3/4-(/-83)
	7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo	
(25)	[b,d] pyran; Synhexyl. Peyote	7/15+
(25)		/415^
	Meaning all parts of the plant presently classified	
	botanically as Lophophora williamsii Lemaire, whether	L
	growing or not; the seeds thereof; any extract from any part of such plant; and every compound,	
	manufacture, salts, derivative, mixture or	
	preparation of such plant, its seeds or extracts.	
	(Interprets 21 USC 812 (c), Schedule I (c) (12)).	
(26)	N-ethyl-3-piperidyl benzilate	7182*
(27)	N-methyl-3-piperidyl benzilate	
(28)	Psilocybin	7437*
(29)	Psilocyn	
(30)	Ethylamine Analog of phencyclidine	
(00)//	Some trade or other names:	7455
	N-ethyl-1-phenylcyclohexylamine,	
	<pre>(phenylcyclohexyl)ethylamine; N-(1-phenylcyclohexyl)</pre>	
	ethylamine; cyclohexamine; PCE.	
(31)	Pyrrolidine Analog of phencyclidine	7458*
	Some trade or other names: 1-(1-phenylcyclohexyl)-	
	pyrrolidine; PCPy; PHP	
(32)	Thiophene Analog of phencyclidine	7470*
	Some trade or other names: 1-[1-(2-thienyl)	
	cyclohexyl] Piperidine; 2-Thienyl analog of	
	phencyclidine; TPCP; TCP.	
(33)	1-[1-(2-Thienyl)cylcohexyl]pyrrolidine	7473-(9-89)
	Some other trade or other names: TCPy.	
(34)	N,N-Diallyl-5-Methoxytryptamine; Some trade or other	names:
	5-MeO DALT; 5-Methoxy-DALT.	
(35)		
	methyl]ethanamine; 25C-NBOMe	
(36)	2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)	
	methyl]ethanamine; 25I-NBOMe	
(37)	2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine; 2C-E	
(38)	2-(2,5-Dimethoxy-4-methylphenyl)ethanamine; 2C-D	
(39)	2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine; 2C-C	
(40)	2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine; 2C-I	7518
(41)	2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine;	
( 4 0 )	2C-T-2	7385
(42)	2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine;	
(12)	2C-T-4	
(43)	2-(2,5-Dimethoxyphenyl)ethanamine; 2C-H	
(44)	2-(2,5-Dimethoxy-4-nitro-phenyl) ethanamine; 2C-N	/521
(45)	2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine;	7504
1161	2C-P	
(46)	2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)et	manamine;
(47)	25B-NBOMe	.11
(47)	2-[[[2-(4-bromo-2,5-dimethoxyphenyl)ethyl]amino]methy	TI-buenoT;

- 25B-NBOH
- (48) 2-[[[2-(4-iodo-2,5-dimethoxyphenyl)ethyl]amino]methyl]-phenol; 25I-NBOH
- (49) 2-(4-ethyl-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)
  methyl]ethanamine; 25E-NBOMe
- (50) 2-(2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl) methyl]ethanamine; 25H-NBOMe
- (51) 2-[[[2-(4-chloro-2,5-dimethoxyphenyl)ethyl]amino]methyl]phenol; 25C-NBOH
- (52) 2-[[[2-(2,5-dimethoxyphenyl)ethyl]amino]methyl]-phenol; 25H-NBOH
- (e) <u>Depressants</u>: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:
  - (1) Phenazepam
  - (2) gamma-hydroxybutyric acid (some other names include
    GHB; gamma-hydroxybutyrate; 4-hydroxybutyrate;
    4-hydroxydutanoic acid; sodium oxybate; sodium
    oxybutyrate), and its known precursors and analogs -- 2010-(2-01)
  - (3) Mecloqualone ----- 2572\*
  - (4) Methaqualone ----- 2565\*
  - (5) Etizolam
  - (6) Clonazolam
  - (7) Flualprazolam
  - (8) Flubromazepam
  - (9) Flubromazolam
- (f) <u>Stimulants</u>: (a)Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers:
  - (1) Cathinone ----- 1235-(3-88)
  - (2) (<u>+</u>) CIS-4-Methylaminorex [(<u>+</u>)CIS-4,5-dihydro-4methyl-5-phenyl-2-oxazolamine] ----- 1590-(6-90)
  - (3) Fenethylline ----- 1503-(9-81)
  - (4) N-Benzylpiperazine----- 7493-(1-05) Some trade or other names: BZP, 1-Benzylpiperazine
  - (5) N-ethylamphetamine ------ 1475-(6-82)
  - (6) N-[1-(1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl), its optical isomers, salts and salts of isomers ----- 9818-(2-86)
  - (7) N-[1-(2-thienyl)methyl-4-piperidyl)-N-phenylpropan-mide (thenylfentanyl), its optical isomers, salts and salts of isomers ------ 9834-(2-86)
  - (8) N, N, Dimethylamphetamine (some other names: N, N Alpha-trimethylbenzeneethanamine; N, N, Alphatrimethylphenethylamine), its salts, optical isomers, and salts of optical isomers ----- 1480-(2-89)

- (10) Aminorex (some other names: aminoraphen, 2-amino-5 phenyl-2-oxazoline, or 4,5 dihyrdo-5-phenyl-2oxazolamine, its salts, optical isomers, and salts of optical isomers ----- 1585-(12-93)
- (11) Methyl-N-ethylcathinone (MEC)
- (b) Any material, compound, mixture, or preparation, whether produced directly or indirectly from a substance of vegetable origin or independently by means of chemical synthesis or by a combination of extraction and chemical synthesis, that contains any quantity of the following substances, or that contains any of the following substances' analogs, salts, isomers, and salts of isomers when the existence of the analogs, salts, isomers, and salts of isomers is possible within the specific chemical designation, with the following chemical structure is included in Schedule I:
  - (1) 4-Methylmethcathinone (Mephedrone) ----- 1248-(3-11)
  - (2) Methylenedioxypyrovalerone (MDPV) ----- (3-11)
  - 3,4-Methylenedioxy-N-methylcathinone (Methylone)---- 7540-(3-11)
  - (4) 4-Methoxymethcathinone -----
  - (5) 3-Fluoromethcathinone -----(3-11)
  - (6) 4-Fluoromethcathinone or -----(3-11)

  - (7) 1-(1,3-benzodioxol-5-yl)-2-methylamino)butan-1-one (Butylone)
  - (8) Alpha-Pyrrolidinopentiophenone (Alpha-PVP)
  - (9) 4-methyl-N-ethylcathinone (4-MEC)
  - (10) 4-methyl-alpha-pyrrolidinopropiophenone (4-MePPP)
  - (11) 2-(methylamino)-1-phenylpentan-1-one (Pentedrone)
  - (12) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one (Pentylone,MBDP)
  - (13) 4-fluoro-N-methylcathinone (4-FMC, Flephedrone)
  - (14) 3-fluoro-N-methylcathinone (3-FMC)
  - (15) 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one (Naphyrone)
  - (16) Alpha-pyrrolidinobutiophenone ([Alpha]-PBP) or
  - (17) A compound, unless listed in another schedule or a legend drug, that is structurally derived from 2-Amino-phenyl-1-propanone by modification or by substitution:
    - (A) In the phenyl ring to any extent with alkyl, alkoxy, alkylenedioxy, haloalkyl or halide substituents, whether or not further substituted in the phenyl ring by one (1) or more other univalent substituents;
    - (B) At the 3-position with an alkyl substituent; or
    - (C) At the nitrogen atom with alkyl or dialkyl groups, or by inclusion of the nitrogen atom in a cyclic structure.
  - (18) N-Ethylpentylone, or 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)-pentan-
  - (19) 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)propan-1-one (Ethylone)----- 7547
  - (20) 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)-1-butanone(Eutylone)

# Schedule II

- Schedule II shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. Each drug or substance has been assigned the Controlled Substances Code Number set forth opposite it.
- (b) Narcotic Drugs: Substances, vegetable origin or chemical synthesis. Unless specifically excepted or unless listed in another schedule, any of the following substances whether produced directly or indirectly by extraction from

substances of vegetable origin, or independently by means of chemical synthesis, or by combination of extraction and chemical synthesis:

(1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate, excluding apomorphine, dextrorphan, nalbuphine, nalmefene, naloxone and naltrexone and their respective salts, but including the following:

(1)	Raw opium	9600*
(2)	Opium extracts	9610*
(3)	Opium fluid extracts	9620*
(4)	Powdered opium	9639*
(5)	Granulated opium	9640*
(6)	Tincture of opium	9630*
(7)	Codeine	9050*
(8)	Dihydroetorphine	9334*
(9)	Ethylmorphine	9190*
(10)	Etorphine hydrochloride	9059*
(11)	Hydrocodone	9193*
(12)	Hydromorphone	9150*
(13)	Metopon	9260*
(14)	Morphine	9300*
(15)	Oripavine	9330*(9-07)
(16)	Oxycodone	9143*
(17)	Oxymorphone	9652*
(18)	Thebaine	9333*
(19)	Tapentadol	9780-(5-09)
(20)	Noroxymorphone	9668

- (2) Any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical with any of the substances referred to in paragraph (b) (1) of this section, except that these substances shall not include the isoquinoline alkaloids of opium.\*
- (3) Opium poppy and poppy straw.\*
- (4) Coca leaves (9040) and any salt, compound, derivative, or preparation of coca leaves, (including cocaine (9041) and ecgonine (9180) and their salts, isomers, derivatives and salts of isomers and derivatives), and any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical with any of these substances, except that the substances shall not include decocainized coca leaves or extraction of coca leaves, which extractions do not contain cocaine or ecgonine.\*
- (5) Concentrate or poppy straw (the crude extract of poppy straw in either liquid, solid or powder form which contains the phenanthrine alkaloids of the opium poppy), 9670.\*
- (c) Opiates: (Narcotic Drugs) Unless specifically excepted or unless in another schedule, any of the following opiates, including its isomers, esters, ethers, salts, and salts of isomers, esters and ethers whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designations:

  - (10) Isomethadone ----- 9226\*

	dered 5 crans cectanydrocannasinor(dered 5 inc/).	7303
	delta-9-trans-tetrahydrocannabinol(delta-9-THC)]	
	marketing by the U.S. Food and Drug Administration; [(-)	
(2)	Dronabinol in an oral solution in a drug product appro	ved for
	hydroxy-6,6-dimethyl-9H-dibenzo[b,d]pran-9-one].	
	dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-	
	[Another name for nabilone:(+))trans-3-(1,1-	
(1)	Nabilone	7379-(11-87)
	lucinogenic Substances:	
(5)	Secobarbital	2315*
(4)	Phencyclidine	/4/1*
(3)		
(2)	Pentobarbital	
, ,	Glutethimide	
specific cn	emical designation: Amobarbital	0105*
enscific ch	or such saits, isomers, and saits of isomers is possible	MICHIE THE
existence of	of such salts, isomers, and salts of isomers is possible	whenever the
	etem, including its salts, isomers, and salts of isomers	
	the following substances having a depressant effect on	
	iny material, compound, mixture, or preparation which co	
(e) Der	pressants: Unless specifically excepted or unless liste	ed in another
( - /	4 I	
(5)	Methylphenidate	
(4)	Phenmetrazine and its salts	
(3)	Lisdexamefetamine	1205*(7-07)
	of its isomers	
(2)	Methamphetamine, its salts, isomers, and salts	
	of its optical isomers	1100*
(1)	Amphetamine, its salts, optical isomers, and salts	
nervous sys		
	the following substances having a stimulant effect on	the central
	any material, compound, mixture, or preparation which co	
	<pre>imulants: Unless specifically excepted or unless listed</pre>	
(28)	Thiafentanil	9729
(27)	Sufentanil	9740-(9-81)
	Remittentanil	9/39-(11-96)
(26)	Remifentanil	0730 /11 06
(25)	Racemorphan	
(24)	Racemethorphan	
(23)	Piminodine	
(22)	Phenazocine	9715*
\2 1	phenylpiperidine-4-carboxylic acid	9234*
(21)	Pethidine-Intermediate-C, 1-methyl-4-	2233
(-3)	phenylpiperidine-4-carboxylate	9233*
(20)	Pethidine-Intermediate-B, ethyl-4-	
( /	methyl-4-phenylpiperidine	9232*
(19)	Pethidine-Intermediate-A, 4-cyano-1-	
(18)	Pethidine (Meperidine)	9230*
	carboxylic acid	9802*
	morpholino-1, 1-diphenylpropane-	
(17)	Moramide-Intermediate, 2-methyl-3-	
	dimethylamino-4, 4-diphenyl butane	9254*
(16)	Methadone-Intermediate, 4-cyano-2-	
(15)	Methadone	9250*
(14)	Metazocine	
(13)	Levorphanol	
(12)	Levomethorphan	
( = = /	25 vo dipinooty internation ( in in in )	5010 (12 55)

(11) Levo-alphacetylmethadol (LAAM) ----- 9648-(12-93)

- Immediate Precursor: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances:
  - Immediate precursor to Amphetamine and Methamphetamine:
    - Phenylacetone ----- 8501-(3-80) Some trade or other names: phenyl-2-propanone; P2P; benzyl methyl Ketone; methyl benzyl Ketone.
  - Immediate precursor to Phencyclidine (PCP):
    - (i) 1-phenylcyclohexylamine ----- 7460\*
    - (ii) 1-piperidinocyclohexanecarbonitrile (PCC) ----- 8603\*
  - Immediate precursor to Fentanyl: (3)
    - (i) 4-anilino-N-phenethylpiperidine(ANPP) ----- 8333\*(08-10)
    - (ii) N-phenyl-N-(piperidin-4-yl)propionamide (norfentanyl) ----- 8366

# Schedule III

- (a) Schedule III shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. Each drug or substance has been assigned the DEA Controlled Substances Code Number set forth opposite it.
- (b) Stimulants: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position, or geometric), and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:
  - (1) Those compounds, mixtures, or preparations in dosage unit form containing any stimulant substances listed in Schedule II which compounds, mixtures, or preparations were listed on August 25. 1971, as excepted compounds under Section 308.32, and any other drug of the quantitative composition shown in that list for those drugs or which is the same except that it contains a lesser quantity of controlled substances----- 1405\*

(2) Benzphetamine ----- 1228\*

- (3) Chlorphentermine ----- 1645\*
- (4) Clortermine ----- 1647\*
- (5) Phendimetrazine ----- 1615\*
- (c) Depressants: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system:
  - (1) Any compound, mixture, or preparation containing:
    - Amobarbital ----- 2126\* (i)
    - (ii) Secobarbital ----- 2316\*
    - (iii) Pentobarbital ----- 2271\*
    - (iv) Embutramide ----- 2020\*(9-06) or any salt thereof and one or more other active medicinal ingredients which are not listed in any schedule.
  - (2) Any suppository dosage form containing:
    - (i) Amobarbital ----- 2126\*
    - (ii) Secobarbital ----- 2316\*
    - (iii) Pentobarbital ----- 2271\* or any salt of any of these drugs and

		approved by the Food and Drug Administration for marketing only as a suppository.	
	(3)	Any substance which contains any quantity of a derivative of barbituric acid or any salt thereof Chlorhexadol	
	(5)	Any drug product containing gamma hydroxybutyric acid, including its salts, isomers, and salts of isomers, for which an application is approved under section 505 of the Federal Food, Drug, and Cosmetic	
	(6)	Act Ketamine. its salts, isomers, and salts of isomers Some other names for Ketamine: (+-)-2-(2-	
	(7)	Chlorophenyl) -2- (Methylamino) -Cyclohexanone.  Lysergic acid	
	(8)	Lysergic acid amide	
	(9)	Methyprylon	
		fondiethylmethane	
		Sulfonmethane	
		Tiletamine and zolazepam or any salt thereof	
		Some trade or other name for a tiletamine-	( - , - , - , - , - , - , - , - , - , -
		zolazepam combination product: Telazol.	
		Some trade or other names for tiletamine:	
		-2 (ethylamino) -2-(2-thienyl) -cyclohexanone.	
		Some trade or other names for zolazepam: -4(2-fluorophenyl)-6,8-dihydro-1,3,8,-	
		trimethylpyrazolo-[3,4-e] [1,4,]-diazepin-7	
		(1-H)-one. flupyrazapon.	
	(14)	Perampanel	2261-(11-13)
(d)	Nal	orphine	9400*
(e) schedul		cotic drugs: Unless specifically excepted or unless 1:	isted in another
	(1)	any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base	
		or alkaloid, in limited quantities as set forth below:	
		(i) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of	
		opium  (ii) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized	9803*
		therapeutic amounts (iii) Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active	9804*
	(	nonnarcotic ingredients in recognized therapeutic amounts	
		_	

(vi) Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts ————————————————————————————————————	(v)	Not more than 500 milligrams of opium per 100 milliliters or per 100 grams or not more than 25 milligrams per dosage unit, with one or more active nonnarcotic ingredients in recognized therapeutic amounts	9809*
(2) Any material, compound, mixture, or preparation containing any of the following narcotic drugs or their salts, as set forth below:  (1) Buprenorphine	(vi)	milliliters or per 100 grams, with one or more active, nonnarcotic ingredients in recognized	0010+
(ii) Reserved  (f) Anabolic Steroids: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts of isomers is possible within the specific chemical designation: Items 1-28	cont	material, compound, mixture, or preparation aining any of the following narcotic drugs or r salts, as set forth below:	
<pre>another schedule, any material, compound, mixture, or preparation containing any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts of isomers is possible within the specific chemical designation: Items 1-28</pre>			
	another schedule quantity of the isomers whenever specific chemica  (1)  (2)  (3)  (4)  (5)  (6)  (7)  (8)  (9)  (10)  (11)  (12)  (13)  (14)  (15)  (16)  (17)  (18)  (19)  (20)  (21)  (22)  (23)  (24)  (25)  (26)  (27)  (28)  (29)  (30)  (31)	, any material, compound, mixture, or preparation following substances, including its salts, isomers the existence of such salts of isomers is possibl designation: Items 1-28	containing any s, and salts of le within the 4000-(9-91)

(1) Exempt anabolic steroid products: Compounds, mixtures, or preparations that contain an anabolic steroid that have been exempted by the Director: NDC Number Andro-Estro 90-4---- 0536-1605 (1)Androgyn L.A.---- 0456-1005 (2)Component E-H in Process Pellets----- Ivy Labs Inc. (3)Component E-H in Process Granulation----- Ivy Labs Inc. Component TE-S in process Granulation----- Ivy Labs Inc. (5)(6) Component TE-S in process Pellets----- Ivy Labs Inc. depANDROGYN----- 0456-1020 (7)Depo-Testadiol----- 0009-0253 (8) DEPO-T.E.---- 52765-257 (10) depTESTROGEN----- 51698-257 (11) Duomone----- 52047-360 (12) DUO-SPAN II----- 0684-0102 (13) DURATESTRIN----- 43797-016 (14) Essian----- Pharmaceutics (15) Essian H.S.---- Pharmaceutics (16) Esterified Estrogens & Methyltestosterone, USP (0.625 mg/1.25mg)----- Interpharm (17) Esterified Estrogens & Methyltestosterone, USP (1.25mg/2.5mg)----- Interpharm (18) Esterified Estrogens & Methyltestosterone (0.625mg/1.25mg) Tablet----- ANDAPharm (19) Esterified Estrogens & Methyltestosterone (1.25mg/2.5mg) Tablet----- ANDAPharm (20) Estratest----- 0032-1026 (21) Estratest HS----- 0032-1023 (22) Menogen----- 59243-570 (23) Menogen HS----- 59243-560 (24) Methyltestosterone & Esterified Estrogens (2.5mg/1.25Mg)----- Lannett Co (25) Methyltestosterone & Esterified Estrogens (Half Strength) (1.25mg/0.625mg) ----- Lannett Co (26) PAN ESTRA TEST----- 0525-0175 (27) Premarin with Methyltestosterone----- 0046-0879 (28) Premarin with Methyltestosterone----- 0046-0878 (29) Syntest D.S.---- 66576-231 (30) Stntest H.S.----- 66576-230 (31) Synovex H in process bulk pellets----- Syntex Animal (32) Synovex H in process granulation----- Syntex Animal (33) Synovex Plus in process granulation----- Fort Dodge (34) Synovex Plus in process bulk pellets----- Fort Dodge (35) TEST-ESTRO Cypionates----- 0536-9470 (36) Testoderm with Adhesive 4mg/d----- Alza Corp. (37) Testoderm 4mg/d----- 17314-4608 (38) Testoderm 6mg/d----- 17314-4609 (39) Testoderm with Adhesive 6mg/d----- 17314-2836 (40) Testoderm in process film----- Alza Corp. (41) Testoderm with Adhesive in process film----- Alza Corp. (42) Testosterone Cypionate/Estradiol Cypionate injection----- 54274-530 (43) Testosterone Cypionate/Estradiol Cypionate injection----- 0182-3069 (44) Testosterone Cyp 50 Estradiol Cyp 2----- 0814-7737 (45) Testosterone Cypionate/Estradiol Cypionate injection----- 0364-6611 (46) Testosterone Cypionate/Estradiol Cypionate

	(47)	Testosterone Enanthate/Estradiol Valerate injection	0192_3073
	(48)	Testosterone Enanthate/Estradiol Valerate	
		injection	0364-6618
	(49)	Testosterone Enanthate/Estradiol Valerate injection	0400 0360
	(50)	3	
	(51)		
403			-
(2)		rinary Anabolic Steroid Implant Products:	
		plic steroid products expressly intended for nistration through implants in cattle or other	
		man species exempted by the Director.	
			NDC/DIN
	(1)	Component E-H	021641-002
	(2)	Component E-H	
	(3)	Component TE-S	
	(4)	Component T-H	
	(5)	Component T-S	
	(6)	F-TO	
	(7)	Finaplix-H	
	(8)	Finaplix-S	
	(9)	Heifer-old	Boehringer
	(10)	Heifer-old	Ingelheim
	(11) (12)	Heifer-old Implus-H	IVY Lab.
	(12)	Implus-H	
	(13)	Implus-II	01968327
	(14)	Masculinizing Feed for Fish (Invesitigational) -	
	(15)	Revalor-G	12799-811
	(16)	Revalor-H	
	(17)	Revalor-S	
	(18)	Synovex H	
	(19)	Synovex H	Syntex
	(20)	Synovex Plus	
	Tilar	via Sex Reversal Feed (investigational)	Zeigier Bros.

injection----- 0402-0257

If veterinary products that are granted exempted status are subsequently distributed with the intent that they be used in humans, the distribution would be subject to the criminal sanctions of the CSA despite the drugs' exempted status.

# (g) <u>Hallucinogenic substances</u>:

# Schedule IV

(a) Schedule IV shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name or brand name designated, listed in this section. Each drug or substance has been assigned the DEA Controlled Substances Code Number set forth opposite it.

- (b) <u>Narcotic drugs</u>: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below:
  - (1) Not more than 1 milligram of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit.----- 9167\*
  - (2) Dextro propoxyphene (alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2-propionoxybutane) ----- 9278-(11-87)
- (c) <u>Depressants</u>: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

(1)	Alprazolam	
(2)	Barbital	
(3)	Bromazepam	2748-(1-85)
(4)	Camazepam	
(5)	Chloral betaine	
(6)	Chloral hydrate	
(7)	Chlordiazepoxide	2744*
(8)	Clobazam	
(9)	Clonazepam	
(10)	Clorazepate	
(11)	Clotiazepam	2752-(1-85)
(12)	Cloxazolam	2753-(1-85)
(13)	Delorazepam	
(14)	Diazepam	
(15)	Dichloralphenazone	2467-(10-02)
(16)	Estazolam	
(17)	Ethchlorvynol	2540*
(18)	Ethinamate	
(19)	Ethyl loflazepate	
(20)	Fludiazepam	2759-(1-85)
(21)	Flunitrazepam	2763-(1-85)
(22)	Flurazepam	
(23)	Fospropofol	2138-(11-09)
(24)	Halazepam	2762-(6-82)
(25)	Haloxazolam	2771-(1-85)
(26)	Ketazolam	2772-(1-85)
(27)	Loprazolam	2773-(1-85)
(28)	Lorazepam	2885*
(29)	Lormetazepam	
(30)	Mebutamate	
(31)	Medazepam	
(32)	Meprobamate	2820*
(33)	Methohexital	2264*
(34)	Methylphenobarbital (mephorbarbital)	2250*
(35)	Midazolam	2884-(1-85)
(36)	Nimetazepam	
(37)	Nitrazepam	2834-(1-85)
(38)	Nordiazepam	2838-(1-85)
(39)	Oxazepam	
(40)	Oxazolam	
(41)	Paraldehyde	
(42)	Petrichloral	
(43)	Phenobarbital	2285*

(44)	Pinazepam	2883-(1-85)
(45)	Prazepam	2764*
(46)	Quazepam	2881-(11-86)
(47)	Temazepam	2925-(9-81)
(48)	Tetrazepam	2886-(1-85)
(49)	Triazolam	2887-(7-83)
(50)	Zaleplon	2781-(9-99)
(51)	Zolpidem	2783-(12-93)
(52)	Zopiclone	2784-(01-06)
(53)	Alfaxalone	2731-(02-14)
(54)	Carisoprodol	8192-(4-97)
(55)	Tramadol	9752-(8-07)
(56)	Suvorexant	2223-(8-14)
(57)	Brexanolone	2400
(58)	Lemborexant	2245

- (d) **Fenfluramine**: Any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers (whether optical, position, or geometric), and salts of such isomers, whenever the existence of such salts, isomers, and salts of isomers is possible:
  - (1) Fenfluramine ----- 1670\*
- (e) <u>Stimulants</u>: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position, or geometric), and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:
- (f) Other substances: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts; isomers whether optical, position, or geometric), and salts of such isomers, whenever the existence of such salts, isomers, and salts of isomers is possible:
  - (1) Pentazocine ----- 9709-(4-79)
  - (2) Butorphanol ------ 9720-(4-97)
  - (3) Nalbuphine ----- (4-97)
  - (4) Eluxadoline ----- 9725

# Schedule V

- (a) Schedule V shall consist of the drugs and other substances by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section.
- (b) Narcotic Drugs: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation containing any of the following narcotic drugs and their salts, as set forth below.

  \*\*Reserved\*\*
- (c) Narcotic drugs containing nonnarcotic active medicinal ingredients. Any compound, mixture, or preparation containing any of the following limited quantities of narcotic drugs or salts thereof, which shall include one or more nonnarcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture, or preparation valuable medicinal qualities other than those possessed by the narcotic drug alone:
  - (1) Not more than 200 milligrams of codeine per 100 milliliters or per 100 grams.
  - \* (2) Not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams.
  - \* (3) Not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams.
  - \* (4) Not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit.
  - \* (5) Not more than 100 milligrams of opium per 100 milliliters or per 100 grams.
  - \* (6) Not more than 0.5 milligrams of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit.
- (d) <u>Stimulants</u>: unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having stimulant effect on the central nervous system, including its salts, isomers and salts of isomers:
  - (1) Pyrovalerone ----- 1485-(3-88)
  - (2) Ephedrine:a -{-(Methylamino)ethyl}benzene-methanol;
     a-{-(methylamino) ethyl}benzyl alcohol;
     2-methylamino-1-phenyl-1-propanol;
     1-phenyl-1-hydroxy-2-methylaminopropane;
     1-phenyl-2-methylaminopropanol;
     a hydroxy-b-methylaminopropylbenzene;
     a product which occurs in the Chinese herb
     Ma Huang (Ephedra vulgaris, Ephedra sinica Stapf.,
     Ephedra equisetina Bunge, Gnetaceae) in several
     other Ephedra spp.
  - (3) Phenylpropanolamine ----- (7-05)
  - (4) Pseudoephedrine ----- (7-05)

Pursuant to Ark. Code Ann. \$ 5-64-212 as amended in 2005, this Schedule V classification shall NOT apply to any ephedrine, phenylpropanolamine, or pseudoephedrine in liquid, liquid capsule, or liquid gel capsule form. However, sales limits mandated by statute shall apply to all products with ephedrine, phenylpropanolamine, or pseudoephedrine as a listed ingredient regardless of the dosage form.

(e) **Depressants:** Unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers:

(1)	Pregabalin [(S)-3-(aminomethyl)-	
	5-methylhexanoic acid)	2782-(01-06)
(2)	Lacosamide	2746-(05-09)
(3)	Brivaracetam	2710
(4)	Lasmiditan	2790
/ E \	Q	0700

#### (f) Other substances:

# Schedule VI\*\*

- (a) In addition to any substance placed in Schedule VI by the Director of the Department of Health under § 5-64-214, any material, compound, mixture, or preparation, whether produced directly or indirectly from a substance of vegetable origin or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis, that contains any quantity of the following substances, or that contains any of their salts, isomers, and salts of isomers when the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation, is included in Schedule VI:
  - (1) Marijuana
  - (2) Tetrahydrocannabinols, unless the tetrahydrocannabinol is:
    - (A) Contained in hemp-derived cannabidiol;
    - (B) Not more than three-tenths of one percent (0.3%) of the hempderived cannabidiol on a dry weight basis as verified by a nationally accredited laboratory for quality, purity and accuracy standards; and
    - (C) Not approved by the United States Food and Drug Administration for marketing as a medication;
  - (3) A synthetic equivalent of:
    - (A) The substance contained in the Cannabis plant; or
    - (B) The substance contained in the resinous extractives of the genus Cannabis;
  - (4) Salvia divinorum or Salvinorin A, which includes all parts of the plant presently classified botanically as Salvia divinorum, whether growing or not, the seeds of the plant, any extract from any part of the plant, and every compound, manufacture, derivative, mixture, or preparation of the plant, its seeds, or its extracts, including salts, isomers, and salts of isomers when the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation;
  - (5) Synthetic substances, derivatives, or their isomers in the chemical structural classes described below in subdivisions (a)(5)(A)-(J) of this section and also specific unclassified substances in subdivision (a)(5)(K) of this section. Compounds of the structures described in this subdivision (a)(5), regardless of numerical designation of atomic positions, are included in this subdivision (a)(5). The synthetic substances, derivatives, or their isomers included in this subdivision (a)(5) are:
    - (A) (i) Tetrahydrocannabinols, including without limitation the following:
      - (a) Delta-1 cis or trans tetrahydrocannabinol, and its optical isomers;
      - (b) Delta-6 cis or trans tetrahydrocannabinol, and its optical isomers; and
      - (c) Delta-3.4 cis or trans tetrahydrocannabinol, and its optical isomers.
      - (ii) Dronabinol in sesame oil and encapsulated in a soft gelatin capsule in a drug product approved by the United

States Food and Drug Administration is not a tetrahydrocannabinol under this subdivision (a)(5)(A);

- (B) Naphthoylindoles, or any compound structurally derived from 3-(1-naphthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation the following
  - (i) JWH-007, or 1-pentyl-2-methyl-3-(1-naphthoyl)indole;
  - (ii) JWH-015, or 1-Propyl-2-methyl-3-(1-naphthoyl)indole;
  - (iii) JWH-018, or 1-Propyl-3-(1-naphthoyl)indole;
  - (iv) JWH-019, or 1-Hexyl-3-(1-naphthoyl)indole;
  - (v) JWH-073, or 1-Butyl-3-(1-naphthoyl)indole;
  - (vi) JWH-081, or 1-Pentyl-3-(4-methoxy-1-naphthoyl)indole;
  - (vii) JWH-098, or 1-pentyl-2-methyl-3-(4-methoxy-1naphthoyl)indole
  - (viii) JWH-122, or 1-Pentyl-3-(4-methyl-1-naphthoyl)indole;
  - (ix) JWH-164, or 1-pentyl-3-(7-methoxy-1-naphthoyl)indole;
  - (x) JWH-200, or 1-[2-(4-morpholiny)ethyl]-3-(1-naphthoyl)
    indole;
  - (xi) JWH-210, or 1-Pentyl-3-(4-ethyl-1-naphthoyl)indole;
  - (xii) JWH-398, or 1-Pentyl-3-(4-chloro-1-naphthoyl)indole;
  - (xiii) AM-2201, or 1-(5-fluoropentyl)-3-(1-naphthoyl)indole;
  - (xiv) MAM2201, or (1-(5-fluoropentyl)-1H-indol-3-yl)(4-methyl-1-naphthalenyl)-methanone; and
  - (xv) EAM2201, or (1-(5-fluoropentyl)-1H-indol-3-yl)(4-ethyl-1-naphthalenyl)-methanone;
  - (xvi) THJ-2201, or [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone;
- (C) Naphthylmethylindoles, or any compound structurally derived from an H-indol-3-yl-(1-naphthyl) methane by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation the following:
  - (i) JWH-175, or 1-Pentyl-1H-indol-3-yl-(1-naphthyl)methane; and
  - (ii) JWH-184, or 1-Pentyl-1H-3-yl-(4-methyl-1naphthyl)methane;
- (D) Naphthoylpyrroles, or any compound structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation JWH-307, or (5-(2-fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone;
- (E) Naphthylmethylindenes, or any compound structurally derived from 1-(1-napthylmethyl)indene with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-

- piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation JWH-176, or E-1-[1-(1-Naphthalenylmethylene)-1H-inden-3-yl]pentane;
- (F) Phenylacetylindoles, or any compound structurally derived from 3-phenylacetylindole by substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent, including without limitation the following:
  - (i) JWH-201, or 2-(4-methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone;
  - (ii) JWH-203, or 1-Pentyl-3-(2-chlorophenylacetyl)indole;
  - (iii) JWH-250, or 1-Pentyl-3-(2-methoxyphenylacetyl)indole;
  - (iv) JWH-251, or 1-Pentyl-3-(2-methylphenylacetyl)indole; and
  - (v) RCS-8, or 1-(2-cyclohexylethyl)-3-(2methoxyphenylacetyl)indole;
- (G) Cyclohexylphenols, or any compound structurally derived from 2-(3-hydroxycyclohexyl)phenol by substitution at the 5-position of the phenolic ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not substituted in the cyclohexyl ring to any extent, including without limitation the following:
  - (i) CP 47,497 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3hydroxycyclohexyl]-phenol;
  - (ii) Cannabicyclohexanol or CP 47,497 C8 homologue, or 5-(1,1dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol;
    and
  - (iii) CP 55,940, or 5-(1,1-dimethylheptyl)-2-[(1R,2R)-5hydroxy-2-(3-hydroxypropyl)cyclohexyl]-phenol;
- (H) Benzoylindoles, or any compound structurally derived from a 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent, including without limitation the following:
  - (i) AM-694, or 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole;
  - (ii) RCS-4, or 1-Pentyl-3-(4-methoxybenzoyl)indole;
  - (iii) WIN-48,098 or Pravadoline, or (4-Methoxyphenyl)-[2methyl-1-(2-(4-morpholinyl)ethyl)indol-3-y]methanone;
  - (iv) AM-2233, or 1-[(N-methylpiperidin-2-yl)methyl]-3-(2iodobenzoyl)indole; and
  - (v) RCS-4 (C4 homologue) or (4-methoxyphenyl)(1-butyl-1Hindol-3-yl)-methanone;
- (I) Adamantoylindoles, or Adamantoylindazoles, including Adamantyl Carboxamide Indoles and Adamantyl Carboxamide Indazoles, or any compound structurally derived from 3-(1-adamantoyl) indole, 3-(1-adamantoyl) indazole, or 3-(2-adamantoyl)indole by substitution at a nitrogen atom of the indole or indazole ring with alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl,cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl, whether or not

further substituted in the indole or indazole ring to any extent and whether or not substituted in the adamantly ring to any extent, including without limitation the following:

- (i) AM-1248, or 1-adamantyl-[1-[(1-methylpiperidin-2yl)methyl]indol-3-yl]methanone;
- (ii) AB-001, or 1-adamantyl-(1-pentylindol-3-yl)methanone;
- (iii) JWH-018 adamantyl carboxamide, or 1-pentyl-Ntricyclo[3.3.1.13,7]dec-1-yl-1H-indole-3-carboxamide, some other names: 2NE1;
- (iv) AKB-48, or N-(1-adamantyl)-pentyl-1H-indazole-3carboxamide;
- (vi) STS-135, or N-(1-adamantyl)-1-(5-fluoropentyl)indole-3carboxamide;
- (J) Tetramethylcyclopropylcarbonylindoles or any compound structurally derived from 3-(2,2,3,3-tetramethylcyclopropylcarbonyl) indole by substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent, including without limitation the following:
  - (i) UR-144, or (1-pentylindol-3-y1)-(2,2,3,3tetramethylcyclopropyl)methanone;
  - (ii) XLR-11, or [1-(5-fluoropenty1)-1H-indol-3-y1]-(2,2,3,3tetramethylcyclopropy1)methanone;
  - (iii) A-796,260, or [1-(2-morpholin-4-yl-ethyl)-1H-indol-3yl](2,2,3,3-tetramethylcyclopropyl)methanone;
  - (iv) 5-Chloro-UR-144, or ([-(5-chloropentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone;
  - (v) 5-Bromo-UR-144, or [1-(5-bromopentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone; and
  - (vi) A-834,735, or 1-(tetrahydropyran-4-ylmethyl)-1H-indol-3yl]-(2,2,3,3-tetramethylcyclopropyl)methanone;
- (K) Unclassified Synthetic Cannabinoids, including without limitation the following:
  - (i) CP 50556-1 hydrochloride, or [(6S,6aR,9R,10aR)-9-hydroxy-6-methyl-3-[(2R)-5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl] acetate;
  - (ii) HU-210, or (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl3-(2-methyloctan-2-yl)-6a,7,10,10atetrahydrobenzo[c]chromen-1-ol;
  - (iii) HU-211, or Dexanabinol, (6aS, 10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;
  - (iv) Dimethylheptylpyran or DMHP;
  - (v) WIN55,212-2, or 2,3-Dihydro-5-methyl-3-(4morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6yl-1-naphthalenylmethanone;

  - (vii) URB754, or 6-methyl-2-[(4-methylphenyl)amino]-1benzoxazin-4-one;

- (ix) URB602, or cyclohexyl N-(3-phenylphenyl)carbamate;
- (x) PB-22, or quinolin-8-yl 1-(5-pentyl)-1H-indole-3carboxylate;
- (xi) 5F-PB-22, or quinolin-8-yl 1-(5-fluoropentyl)-1Hindole-3-carboxylate;
- (xii) BB-22, or quinolin-8-yl 1-(cyclohexylmethyl)-1Hindole-3-carboxylate;
- (xiii) NNEI (MN-24), or N-1-naphthalenyl-1-pentyl-1H-indole-3-carboxamide;
- (xiv) 5F-NNEI, or 1-(5-fluoropentyl)-N-(naphthalene-1-yl)1H-indole-3-carboxamide;
- (xv) 5-Fluoro-AMB, or n-[[1-(5-fluoropentyl)1H-indazol-3-yl]carbonyl]-L-valine methyl
  ester ----- 7033
- (xvi) MMB-CHMICA, or methyl-(1-cyclohexylmethyl)-1H-indole-3carbonyl)-L-valinate;
- (xvii) 5-Fluoro-ADB, or methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate; ----- 7034
- (xviii) 5-Fluoro-MDMB-PICA, or methyl 2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate;
- (xix) MDMB-CHMICA, or methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate; ----- 7042
- (xx) FUB-AMB, or methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate; ---- 7021
- (xxi) MDMB-FUBINACA, or methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate; ----- 7020
- (xxii) AB-PINACA, or N-(1-amino-3-methyl-1-oxobutan-2-yl)1-pentyl-1H-indazole-3-caroboxamide;
- (xxiii) AB-CHMINACA, or N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide;
- (xxiv) MAB-CHMINACA, or N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide;
- (xxv) AB-FUBINACA, or N-(1-amino-3-methyl-1-oxobutan-2-yl)1-(4-fluorobenzyl)-1H-indazole-3-carboxamide;
- (xxvi) ADB-PINACA, or N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide;
- (xxvii) 5F-CUMYL-PINACA, or 1-(5-fluoropentyl)-N-(2phenylpropan-2-yl)-1H-indazole-3-carboxamide;
- (xxviii) ADB-FUBINACA, or N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide;----- 7010
- (xxix) 4-Fluoro MDMB-BUTINACA, or methyl(S)-2-(1-(4fluorobutyl)-1H-indazole-3-carboxamido)-3,3dimethylbutanoate;
- (6) A synthetic substance, derivative, or its isomers with:
  - (A) Similar chemical structure to any substance described in subdivisions (a)(1)-(5) of this section; or
  - (B) Similar pharmacological effects to any substance described in subdivisions (a)(1)-(5) of this section.
- (b) However, director shall not delete a controlled substance listed in this section from Schedule VI.

(c) (1) If notice has been given to the director that the United States Food and Drug Administration has designated, rescheduled, or descheduled a marijuanaderived substance under federal law and approved for marketing the marijuanaderived substance as a prescription medication, the director shall consider the designation, rescheduling, or descheduling of the marijuanaderived substance under this chapter.

<sup>\*-</sup>Scheduled before April, 1979.

<sup>\*\*-</sup>Schedule VI is revised to conform to Act 329 of 2013.